A study of phosphorylated ERK1/2 and COX-2 in early stage (T1-T2) oral squamous cell carcinomas

Journal of Oral Pathology and Medicine

Volumn 37, Issue 9, 2008, Pages 535-542

  Søland, Tine M ^a   Husvik, Camilla ^a   Koppang, Hanna Strømme ^a   Boysen, Morten ^a   Sandvik, Leiv ^a   Clausen, Ole Petter Fraas ^b   Christoffersen, Thoralf ^a   Bryne, Magne ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Cyclo oxygenase 2; Invasive front; Mitogen activated protein kinase; Oral cancer; Prognosis

Indexed keywords

CYCLOOXYGENASE 2; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; CYTOPLASM; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MORPHOMETRICS; MOUTH CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SQUAMOUS CELL CARCINOMA; TUMOR VOLUME; WESTERN BLOTTING; WORLD HEALTH ORGANIZATION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CYCLOOXYGENASE 2; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MOUTH NEOPLASMS; NEOPLASM INVASIVENESS; PHOSPHORYLATION; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 51349084950     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2008.00656.x     Document Type: Article

References (45)

1. Yamamoto E, Kohama G, Sunakawa H, Iwai M, Hiratsuka H. Mode of invasion, bleomycin sensitivity, and clinical course in squamous cell carcinoma of the oral cavity. Cancer 1983 51 : 2175 80.
2. Bryne M, Koppang HS, Lilleng R, Kjaerheim A. Malignancy grading of the deep invasive margins of oral squamous-cell carcinomas has high prognostic value. J Pathol 1992 166 : 375 81.
3. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001 411 : 375 9.
4. Ueno H, Murphy J, Jass JR, Mochizuki H, Talbot IC. Tumour 'budding' as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology 2002 40 : 127 32.
5. Christofori G. New signals from the invasive front. Nature 2006 441 : 444 50.
6. Mueller MM, Fusenig NE. Friends and foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 2004 4 : 839 49.
7. Bhowmick NA, Moses HL. Tumor-stroma interactions. Curr Opin Genet Dev 2005 15 : 97 101.
8. Baglole CJ, Ray DM, Bernstein SH, et al. More than structural cells, fibroblasts create and orchestrate the tumor microenvironment. Immunol Invest 2006 35 : 297 325.
9. Bryne M, Boysen M, Alfsen C, et al. The invasive front of carcinomas. The most important area for tumour prognosis? Anticancer Res 1998 18 : 4757 64.
10. Bankfalvi A, Piffko J. Prognostic and predictive factors in oral cancer: the role of the invasive tumour front. J Oral Pathol Med 2000 29 : 291 8.
11. Wang D, DuBois RN. Prostaglandins and cancer. Gut 2006 55 : 115 22.
12. Fang JY, Richardson BC. The MAPK signalling pathways and colorectal cancer. Lancet Oncol 2005 6 : 322 7.
13. Seger R, Krebs EG. The MAPK signaling cascade. FASEB J 1995 9 : 726 35.
14. Wilkinson MG, Millar JBA. Control of the eukaryotic cell cycle by MAP kinase signaling pathways. FASEB J 2000 14 : 2147 57.
15. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 2001 410 : 37 40.
16. Vial E, Pouysségur J. Regulation of tumor cell motility by ERK mitogen-activated protein kinases. Ann N Y Acad Sci 2004 1030 : 208 18.
17. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007 26 : 3291 310.
18. Handra-Luca A, Bilal H, Bertrand JC, Fouret P. Extra-cellular signal-regulated ERK-1/ERK-2 pathway activation in human salivary gland mucoepidermoid carcinoma: association to aggressive tumor behavior and tumor cell proliferation. Am J Pathol 2003 163 : 957 67.
19. Givant-Horwitz V, Davidson B, Lazarovici P, et al. Mitogen-activated protein kinases (MAPK) as predictors of clinical outcome in serous ovarian carcinoma in effusions. Gynecol Oncol 2003 91 : 160 72.
20. Milde-Langosch K, Bamberger AM, Rieck G, et al. Expression and prognostic relevance of activated extracellular-regulated kinases (ERK1/2) in breast cancer. Br J Cancer 2005 92 : 2206 15.
21. Albanell J, Codony-Servat J, Rojo F, et al. Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor-α expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. Cancer Res 2001 61 : 6500 10.
22. Richter P, Böhmer FD, Hindermann W, et al. Analysis of activated EGFR signalling pathways and their relation to laminin-5 γ2 chain expression in oral squamous cell carcinoma (OSCC). Histochem Cell Biol 2005 124 : 151 60.
23. Wang L, Liu T, Nishioka M, Aguirre RL, Win SS, Okada N. Activation of ERK1/2 and cyclin D1 expression in oral tongue squamous cell carcinomas: relationship between clinicopathological appearances and cell proliferation. Oral Oncol 2006 42 : 625 31.
24. Chan G, Boyle JO, Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 1999 59 : 991 4.
25. Shibata M, Kodani I, Osalki M, et al. Cyclo-oxygenase-1 and-2 expression in human oral mucosa, dysplasias and squamous cell carcinomas and their pathological significance. Oral Oncol 2005 41 : 304 12.
26. Pannone G, Bufo P, Caiaffa MF, et al. Cyclooxygenase-2 expression in oral squamous cell carcinoma. Int J Immunopathol Pharmacol 2004 17 : 273 82.
27. 6 integrin-dependent oral squamous carcinoma invasion. Cancer Res 2006 66 : 10833 42.
28. Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K, DuBois RN. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 2005 23 : 254 66.
29. de Groot DJA, de Vries EGE, Groen HJM, de Jong S. Non-steroidal anti-inflammatory drugs to potentiate chemotherapy effects: From lab to clinic. Crit Rev Oncol Hematol 2007 61 : 52 69.
30. Ranelletti FO, Almadori G, Rocca B, et al. Prognostic significance of cyclooxygenase-2 in laryngeal squamous cell carcinoma. Int J Cancer 2001 95 : 343 9.
31. Lim SC, Zhang S, Ishii G, et al. Predictive markers for late cervical metastasis in stage I and II invasive squamous cell carcinoma of the oral tongue. Clin Cancer Res 2004 10 : 166 72.
32. Pannone G, Sanguedolce F, De MS, et al. Cyclooxygenase isozymes in oral squamous cell carcinoma: a real-time RT-PCR study with clinic pathological correlations. Int J Immunopathol Pharmacol 2007 20 : 317 24.
33. Sakurai K, Urade M, Noguchi K, et al. Prognostic significance of cyclooxygenase-2 and DNA topoisomerase IIalpha expression in oral carcinoma. Head Neck 2007 29 : 1002 9.
34. Atula T, Hedstrom J, Ristimaki A, et al. Cyclooxygenase-2 expression in squamous cell carcinoma of the oral cavity and pharynx: association to p53 and clinical outcome. Oncol Rep 2006 16 : 485 90.
35. Gallo O, Masini E, Bianchi B, Bruschini L, Paglierani M, Franchi A. Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and neck squamous cell carcinoma. Hum Pathol 2002 33 : 708 14.
36. Bayazit YA, Buyukberber S, Sari I, et al. Cyclo-oxygenase 2 expression in laryngeal squamous cell carcinoma and its clinical correlates. ORL J Otorhinolaryngol Relat Spec 2004 66 : 65 9.
37. Itoh S, Matsui K, Furuta I, Takano Y. Immunohistochemical study on overexpression of cyclooxygenase-2 in squamous cell carcinoma of the oral cavity: its importance as a prognostic predictor. Oral Oncol 2003 39 : 829 35.
38. Harmer M. TNM classification of malignant tumors, 3rd edn. Geneva : International Union Against Cancer, 1987.
39. Pindborg JJ, Reichart PA, Smith CJ, van der Waal I. Histological typing of cancer and precancer of the oral mucosa. Berlin : Springer, 1997.
40. Morton RS, Dongari-Bagtzoglou AI. Cyclooxygenase-2 is upregulated in inflamed gingival tissues. J Periodontol 2001 72 : 461 9.
41. Pouyssegur J, Volmat V, Lenormand P. Fidelity and spatio-temporal control in MAP kinase (ERKs) signalling. Biochem Pharmacol 2002 64 : 755 63.
42. Glading A, Koziol JA, Krueger J, Ginsberg MH. PEA-15 inhibits tumor cell invasion by binding to extracellular signal-regulated kinase 1/2. Cancer Res 2007 67 : 1536 44.
43. Formstecher E, Ramos JW, Fauquet M, et al. PEA-15 mediates cytoplasmic sequestration of ERK MAP kinase. Dev Cell 2001 1 : 239 50.
44. Renkonen J, Wolff H, Paavonen T. Expression of cyclo-oxygenase-2 in human tongue carcinoma and its precursor lesions. Virchows Arch 2002 440 : 594 7.
45. Prescott SM, Fitzpatrick FA. Cyclooxygenase-2 and carcinogenesis. Biochim Biophys Acta 2000 1470 : M69 78.